Recruiting PHASE1 INTERVENTIONAL 3-arm NCT05783622

Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies

An Open-Label, Multicenter, Phase 1/1b Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies

Sponsor: Janux Therapeutics

Conditions Colorectal Carcinoma Non-Small Cell Lung Cancer Pancreatic Ductal Adenocarcinoma Renal Cell Carcinoma Small Cell Lung Cancer Squamous Cell Carcinoma of the Head and Neck Triple-negative Breast Cancer

Interventions JANX008

Updated 16 times since 2023 Last updated: Oct 10, 2025 Started: Apr 19, 2023 Primary completion: Jan 31, 2026 Completion: Oct 31, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Colorectal Carcinoma and Non-Small Cell Lung Cancer and is currently actively recruiting participants. Janux Therapeutics leads this study, which shows 16 recorded versions since 2023 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

16 versions recorded

Nov 2025 — Present [monthly]

Recruiting PHASE1
Sep 2025 — Nov 2025 [monthly]

Recruiting PHASE1
Aug 2025 — Sep 2025 [monthly]

Recruiting PHASE1
Apr 2025 — Aug 2025 [monthly]

Recruiting PHASE1
Oct 2024 — Apr 2025 [monthly]

Recruiting PHASE1

▶ Show 11 earlier versions

Sep 2024 — Oct 2024 [monthly]

Recruiting PHASE1
Aug 2024 — Sep 2024 [monthly]

Recruiting PHASE1
Jul 2024 — Aug 2024 [monthly]

Recruiting PHASE1
May 2024 — Jul 2024 [monthly]

Recruiting PHASE1
Apr 2024 — May 2024 [monthly]

Recruiting PHASE1
Mar 2024 — Apr 2024 [monthly]

Recruiting PHASE1
Feb 2024 — Mar 2024 [monthly]

Recruiting PHASE1
Jan 2024 — Feb 2024 [monthly]

Recruiting PHASE1
Aug 2023 — Jan 2024 [monthly]

Recruiting PHASE1
Jun 2023 — Aug 2023 [monthly]

Recruiting PHASE1
Apr 2023 — Jun 2023 [monthly]

Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Janux Therapeutics

Data source: Janux Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ann Arbor, United States , Atlanta, United States , Chapel Hill, United States , Chicago, United States , Cincinnati, United States , Columbus, United States , Dallas, United States , Detroit, United States , Duarte, United States , Houston, United States and 8 more locations